Sugi Predict

Sugi Predict / Compounds / SCHEMBL9912557

SCHEMBL9912557

SCHEMBL9912557

Cn1nc([N+](=O)[O-])c(C[C@H](NC(=O)OC(C)(C)C)C(=O)O)c1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 6/20 0.48
▸ PPARG P37231 5/20 0.48
▸ ACE P12821 2/20 0.48
▸ ITGA4 P13612 1/20 0.43
▸ ITGB7 P26010 1/20 0.43
▸ CTSS P25774 3/20 0.42
▸ CTSK P43235 2/20 0.42
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42
▸ AKT1 P31749 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ PPARD Q03181 2/20 0.41
▸ PTPN1 P18031 1/20 0.40
▸ APP P05067 1/20 0.40
▸ ITGB3 P05106 1/20 0.39
▸ ITGA2B P08514 1/20 0.39
▸ ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9912561 0.89 PPARA (0.40) PPARAPPARGACEITGA4ITGB7
SCHEMBL9912455 0.83 PPARA (0.48) PPARAPPARGACEITGA4ITGB7
SCHEMBL9912516 0.77 ACE (0.51) PPARAPPARGACECTSSCTSK
SCHEMBL14124981 0.76 ACE (0.50) PPARAPPARGACECTSSCTSK
SCHEMBL14052736 0.74 ACE (0.48) PPARAPPARGACECTSSCTSK
SCHEMBL7346390 0.74 PPARA (0.73) PPARAPPARGACECTSSCTSK
SCHEMBL606309 0.73 ACE (0.79) PPARAPPARGACECTSSCTSK
SCHEMBL66220 0.73 ACE (0.79) PPARAPPARGACECTSSCTSK
SCHEMBL21473784 0.73 ACE (0.79) PPARAPPARGACECTSSCTSK
SCHEMBL67020 0.73 ACE (0.79) PPARAPPARGACECTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016059602-A2 METHODS OF TREATING CANCER AND RELATED COMPOSITIONS GLAXO GROUP LIMITED (GB) 2016-04-21 — — WO claimed
WO-2024150738-A1 METHOD FOR DIAGNOSING CANCER 宮崎 徹 2024-07-18 — — WO disclosed
US-20240238377-A1 METHODS OF TUMOUR THERAPY WITH A COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF T-CELL INHIBITORY MOLECULES UNIVERSITAT ZURICH (US) 2024-07-18 — — US disclosed
EP-4398915-A1 PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1 TALEN KNOCKDOWN Iovance Biotherapeutics, Inc. (US) 2024-07-17 — — EP disclosed
CN-110536703-B Combination therapy using anti-AXL antibody-drug conjugates ADC治疗有限公司 2024-07-12 — — CN disclosed
CN-118284432-A Cytotoxicity-inducing therapeutic agents for the treatment of cancer 中外制药株式会社 2024-07-02 — — CN disclosed
US-20240207318-A1 CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES ZHANG YONGLIANG (US) 2024-06-27 — — US disclosed
US-20240191191-A1 METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS IOVANCE BIOTHERAPEUTICS INC (US) 2024-06-13 — — US disclosed
EP-4380968-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING HLA FUSION PROTEINS ImmunOs Therapeutics AG (CH) 2024-06-12 — — EP disclosed
EP-4380595-A1 A MODIFIED HLA-B57 WITH INCREASED EXPRESSION LEVELS ImmunOs Therapeutics AG (CH) 2024-06-12 — — EP disclosed
WO-2013164754-A2 PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS PFIZER INC. (US) 2013-11-07 — — WO disclosed
US-20130295110-A1 PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS PFIZER INC (US) 2013-11-07 — — US disclosed
EP-2591796-A1 Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy Universität Zürich (CH) 2013-05-15 — — EP disclosed
WO-2013055404-A1 MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF CITY OF HOPE (US) 2013-04-18 — — WO disclosed
WO-2013053775-A1 COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF T-CELL INHIBITORY MOLECULES FOR TUMOUR THERAPY Universität Zürich Prorektorat Mnw (CH) 2013-04-18 — — WO disclosed
US-20120302599-A1 KAT ll INHIBITORS PFIZER INC 2012-11-29 — — US disclosed
US-20120302599-A1 KAT ll INHIBITORS PFIZER INC 2012-11-29 — — US disclosed
US-20120302599-A1 KAT ll INHIBITORS PFIZER INC 2012-11-29 — — US disclosed
US-20120301400-A1 MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF CITY OF HOPE 2012-11-29 — — US disclosed
WO-2012073143-A1 KAT II INHIBITORS PFIZER INC. (US) 2012-06-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240191191-A1 METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS CD69, CD209, ICOS PPARA 1823/4885PPARG 1796/4885ACE 4287/4885
US-20120302599-A1 KAT ll INHIBITORS KAT2A, KAT7, KAT5 PPARA 2262/4885PPARG 1504/4885ACE 2952/4885
US-20120301400-A1 MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF FCGR3B, FCGR2A, FCGR1A PPARA 2372/4885PPARG 3556/4885ACE 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.